Trial Profile
A Phase 0 Study in Subjects With Well Controlled Celiac Disease to Assess the Effects of Gluten Digestion With ALV003 (a Protease Enzyme) in Vitro
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Latiglutenase (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Sponsors Alvine Pharmaceuticals
- 15 Oct 2014 New trial record